Hemab Stock

Hemab is a clinical-stage biotech company developing prophylactic therapeutics for serious, underserved bleeding and thrombotic disorders.

Sign up today and learn more about Hemab Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Hemab Stock

Hemab is a company that creates preventative treatments for bleeding and thrombosis problems. The medicines developed by the business aggregate, modify, balance, and at times recruit endogenous clotting components already present in the blood to the site of injury, allowing patients to produce hemostatic plugs or clots to avert life-threatening complications. Hemab Therapeutics was established in 2017 in Copenhagen, Hovedstaden by Johan H. Faber and Mads Behrndt.

Funding History

July 2021$55.0M
February 2023$135M


Board Member

Dan Becker

CTO & Co-Founder

Johan H. Faber

Board Member

Uya Chuluunbaatar

Chief Executive Officer

Benny Sørensen

Chief Financial Officer

Mads Behrndt


Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: